Document Detail

Use of recombinant activated factor VII in massive obstetric haemorrhage.
MedLine Citation:
PMID:  17126006     Owner:  NLM     Status:  MEDLINE    
Massive obstetric haemorrhage is a life-threatening emergency that remains a major cause of maternal mortality. Conventional management is aimed at optimising uterine tone, replacing circulating volume and blood products, and surgery to achieve haemostasis. Recently there have been numerous reports of the (unlicensed) use of recombinant activated factor VII in the management of major obstetric haemorrhage. We report our experience of using it in the treatment of major post-partum haemorrhage in four previously healthy parturients. The published reports of recombinant activated factor VII use in post-partum haemorrhage (unrelated to pre-existing coagulopathies) are compared.
J Haynes; M Laffan; F Plaat
Related Documents :
2268826 - Maternal-infant clinical nurse specialist performance assessment: reliability and valid...
16157116 - Maternal-fetal medicine specialist density is inversely associated with maternal mortal...
16382816 - The effects of kin propinquity on infant mortality.
1914626 - Effect of maternal social support on attachment: experimental evidence.
7668056 - Reducing perinatal mortality in vila central hospital, vanuatu.
10450906 - Acoustic examination of preterm and full-term infant cries: the long-time average spect...
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2006-11-27
Journal Detail:
Title:  International journal of obstetric anesthesia     Volume:  16     ISSN:  0959-289X     ISO Abbreviation:  Int J Obstet Anesth     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2006-12-20     Completed Date:  2007-04-23     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9200430     Medline TA:  Int J Obstet Anesth     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  40-9     Citation Subset:  IM    
Obstetric Anaesthesia Department, Queen Charlotte's and Chelsea Hospital, and Department of Haematology, Hammersmith Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Coagulation Disorders / etiology,  therapy
Cesarean Section / methods
Coagulants / therapeutic use*
Factor VII / therapeutic use*
Factor VIIa
Leiomyoma / complications
Postpartum Hemorrhage / therapy*
Recombinant Proteins / therapeutic use
Uterine Neoplasms / complications
Reg. No./Substance:
0/Coagulants; 0/Recombinant Proteins; 0/recombinant FVIIa; 9001-25-6/Factor VII; EC VIIa
Comment In:
Int J Obstet Anesth. 2007 Jul;16(3):299-300; author reply 300   [PMID:  17509865 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Post dural puncture headache in obstetric patients: experience from a West African teaching hospital...
Next Document:  Anesthesia for cesarean section in a patient with Holt-Oram syndrome.